Name | Number of supported studies | Average coverage | |
---|---|---|---|
adipocyte | 9 studies | 37% ± 10% | |
oligodendrocyte | 7 studies | 28% ± 8% | |
endothelial cell | 6 studies | 19% ± 3% | |
epithelial cell | 6 studies | 30% ± 12% | |
glutamatergic neuron | 5 studies | 42% ± 19% | |
oligodendrocyte precursor cell | 4 studies | 25% ± 7% | |
GABAergic neuron | 3 studies | 43% ± 3% | |
dendritic cell | 3 studies | 25% ± 1% | |
neuron | 3 studies | 25% ± 10% | |
hepatocyte | 3 studies | 41% ± 24% | |
astrocyte | 3 studies | 34% ± 4% | |
interneuron | 3 studies | 42% ± 20% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 6 studies | 36% ± 14% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
ovary | 100% | 1604.74 | 180 / 180 | 100% | 48.07 | 430 / 430 |
esophagus | 100% | 2458.12 | 1443 / 1445 | 100% | 69.96 | 183 / 183 |
lung | 100% | 2391.69 | 577 / 578 | 100% | 55.14 | 1154 / 1155 |
breast | 100% | 3110.61 | 459 / 459 | 100% | 67.85 | 1114 / 1118 |
brain | 100% | 2967.59 | 2639 / 2642 | 100% | 41.66 | 703 / 705 |
prostate | 100% | 2365.72 | 245 / 245 | 100% | 96.29 | 500 / 502 |
intestine | 100% | 2375.83 | 966 / 966 | 99% | 45.02 | 524 / 527 |
bladder | 100% | 1816.33 | 21 / 21 | 99% | 45.30 | 498 / 504 |
uterus | 100% | 2208.56 | 170 / 170 | 99% | 63.52 | 453 / 459 |
stomach | 100% | 1653.53 | 359 / 359 | 99% | 49.80 | 282 / 286 |
pancreas | 100% | 1403.96 | 327 / 328 | 98% | 40.87 | 175 / 178 |
liver | 100% | 2674.37 | 226 / 226 | 97% | 52.95 | 394 / 406 |
thymus | 100% | 1873.68 | 653 / 653 | 95% | 25.94 | 573 / 605 |
kidney | 100% | 1697.99 | 89 / 89 | 94% | 30.78 | 849 / 901 |
skin | 100% | 3503.02 | 1809 / 1809 | 92% | 33.93 | 435 / 472 |
adrenal gland | 99% | 1695.11 | 256 / 258 | 83% | 15.98 | 191 / 230 |
adipose | 100% | 3556.03 | 1204 / 1204 | 0% | 0 | 0 / 0 |
spleen | 100% | 1330.51 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 13.06 | 1 / 1 |
blood vessel | 100% | 1810.69 | 1329 / 1335 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 64.42 | 44 / 45 |
lymph node | 0% | 0 | 0 / 0 | 97% | 31.80 | 28 / 29 |
heart | 90% | 1054.62 | 772 / 861 | 0% | 0 | 0 / 0 |
muscle | 76% | 564.09 | 612 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 66% | 14.53 | 53 / 80 |
peripheral blood | 54% | 887.72 | 505 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0030148 | Biological process | sphingolipid biosynthetic process |
GO_0042761 | Biological process | very long-chain fatty acid biosynthetic process |
GO_0030497 | Biological process | fatty acid elongation |
GO_0035338 | Biological process | long-chain fatty-acyl-CoA biosynthetic process |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0019899 | Molecular function | enzyme binding |
GO_0005515 | Molecular function | protein binding |
GO_0102158 | Molecular function | very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase activity |
GO_0018812 | Molecular function | 3-hydroxyacyl-CoA dehydratase activity |
GO_0004725 | Molecular function | protein tyrosine phosphatase activity |
Gene name | HACD2 |
Protein name | Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase 2 (EC 4.2.1.134) (3-hydroxyacyl-CoA dehydratase 2) (HACD2) (Protein-tyrosine phosphatase-like member B) Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase (EC 4.2.1.134) |
Synonyms | PTPLB |
Description | FUNCTION: Catalyzes the third of the very long-chain fatty acids (VLCFA) elongation four-step cycle (condensation, reduction, dehydration, and reduction). This endoplasmic reticulum-elongation process is characterized by the addition of two carbons to the lipid chain through each cycle. This enzyme catalyzes the dehydration of the 3-hydroxyacyl-CoA intermediate into trans-2,3-enoyl-CoA, within each cycle of elongation. Therefore, it participates in the production of various VLCFAs involved in multiple biological processes as precursors of membrane lipids and lipid mediators. . FUNCTION: Catalyzes the third of the four reactions of the long-chain fatty acids elongation cycle. This endoplasmic reticulum-bound enzymatic process, allows the addition of two carbons to the chain of long- and very long-chain fatty acids/VLCFAs per cycle. This enzyme catalyzes the dehydration of the 3-hydroxyacyl-CoA intermediate into trans-2,3-enoyl-CoA, within each cycle of fatty acid elongation. Thereby, it participates to the production of VLCFAs of different chain lengths that are involved in multiple biological processes as precursors of membrane lipids and lipid mediators. . FUNCTION: Catalyzes the third of the four reactions of the long-chain fatty acids elongation cycle. This endoplasmic reticulum-bound enzymatic process, allows the addition of two carbons to the chain of long- and very long-chain fatty acids/VLCFAs per cycle. This enzyme catalyzes the dehydration of the 3-hydroxyacyl-CoA intermediate into trans-2,3-enoyl-CoA, within each cycle of fatty acid elongation. Thereby, it participates to the production of VLCFAs of different chain lengths that are involved in multiple biological processes as precursors of membrane lipids and lipid mediators. . |
Accessions | ENST00000383657.10 C9JWG1 H7C4K8 ENST00000493515.1 ENST00000469317.1 Q6Y1H2 |